Navigation Links
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Date:4/25/2008

f Executive Officer of Isis. "Conducting an outcome study in parallel with our continued evaluation of the effects of mipomersen on atherogenic lipids will allow us to submit a much stronger NDA for high risk patients. We are confident that mipomersen will bring benefit to patients with high cholesterol and remain committed to its development and commercialization."

"We are pleased that the FDA has given clear direction on what will be required for the approval of mipomersen, and has acknowledged its potential to help high risk patients whose needs are not being met by current therapies," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "Having outcome data earlier on in the development process will be important to patients and serve to enhance the value of this treatment. We plan to engage in discussions with regulatory agencies in Europe and the rest of the world, and look forward to receiving their feedback."

ABOUT MIPOMERSEN

In early 2008, Isis and Genzyme announced that they had entered into a strategic alliance in which Genzyme will develop and commercialize mipomersen. Final contracts are still being negotiated and are expected to be completed this quarter.

Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-cholesterol, being the good form, and low-density lipoproteins, or LDL-cholesterol, and very low-density lipoproteins, or VLDL-cholesterol, being bad forms directly involved in heart disease. Collectively lowering LDL-cholesterol, VLDL-cholesterol, and other bad forms of cholesterol are a key component in the prevention and management of cardiovascular disease.

Mipomersen is currently in phase 3 development for patients with homozygous familial hypercholesterolemia, a disease which crea
'/>"/>

SOURCE Genzyme Corp. and Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 According to the Boost Your Bust book ... women who want to learn how to increase the size of ... of 7 chapters including:, , Chapter 1 – ... Chapter 2 – How Natural Breast Enlargement Works , ... Bigger , Chapter 4 – The Groundwork , ...
(Date:7/14/2014)... Vaginal Mesh lawsuit claims continue to mount ... manufacturers in the U.S. District Court, Southern District of ... complaints are pending against pelvic mesh manufacturers that include ... No. 2325), and C.R. Bard, Inc., (MDL No. 2187). ... lawsuit claims pending, according to statistics from the U.S. ...
(Date:7/14/2014)... that promote mental activity, and moderate physical activity ... development of Alzheimer,s disease and dementia in later ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... 2014 also showed that sleep problems especially ... may increase dementia risk in veterans. Additionally, in ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 Love Digits ... iTunes, called Love Digits. The App brings ancient astrology ... alike to quantify their compatibility using a five-star rating ... two people can instantaneously test their compatibility for love ... measures. , The app’s five-star rating system generates a ...
(Date:7/14/2014)... Summer is the best season of the ... beach, swimming and other outdoor adventures. The promotional product experts ... and healthy all summer long. The promo product gurus at ... must-have custom imprinted products everyone must have on hand this ... sunblock. Sunscreen helps protect skin from harmful UV ...
Breaking Medicine News(10 mins):Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2
... BROOK, Ill. Radiologists who interpret a high volume of ... determining which suspicious lesions are not malignant, according to a ... of Radiology . "Contrary to our expectations, we ... study,s lead author, Diana S.M. Buist, Ph.D., M.P.H., senior investigator ...
... errors isn,t quite as new as it seems. A Johns ... the turn of the last century, has turned up copious ... suggestions for preventing those mistakes in the future. Authors ... Surgery , suggest that such open documentation may have played ...
... MONDAY, Feb. 21 (HealthDay News) -- Implementing practical, environmentally ... could reduce health-care costs without compromising patient safety, says ... facilities are a major source of waste products, producing ... 4 billion pounds a year. Nearly 70 percent of ...
... By Serena Gordon HealthDay Reporter , MONDAY, Feb. ... in northern climates aren,t imaging that their misery is lasting ... for people living in some northern U.S. states, the length ... weeks, and for people living in some areas of Canada, ...
... , MONDAY, Feb. 21 (HealthDay News) -- Seniors who ... researchers say. The study from Rush University in Chicago ... no type of disability at the start of the study ... provided information about their social activities, such as going out ...
... million grant from the National Institutes of Health (NIH) ... biomarkers that may be linked to the development and ... in children. Nationwide Children,s is home to the only ... with an NIH-sponsored clinical study. A hemangioma is ...
Cached Medicine News:Health News:Higher volume reduces false positives in screening mammography 2Health News:Famed neurosurgeon's century-old notes reveal 'modern' style admission of medical error 2Health News:Going 'Green' May Cut Hospital Costs 2Health News:Climate Change Extending Ragweed Season in Colder Climes: Study 2Health News:Climate Change Extending Ragweed Season in Colder Climes: Study 3Health News:Busy Social Life May Stave Off Disability in Elderly 2Health News:$1.9 million NIH grant supports research in the most common soft tissue tumor in children 2
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... privately-held therapeutic device company, today announced that DEKRA and Health ... Matrix for clinical use and sale in Europe and Canada. ... resistant, and absorbable putty designed to rapidly stop bleeding when ... cut bone is a problem in many operative procedures including ...
... announces that a new market research report is available ... Deals Analysis 2011 http://www.reportlinker.com/p0180789/Medical-Equipment-Annual-Deals-Analysis-2011.html ... Summary GlobalData,s "Medical Equipment ... of data and trend analysis on mergers and acquisitions ...
Cached Medicine Technology:ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB® 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 3Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 4Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 5Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 6Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 7Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 8Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 9Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 10Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 11Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 12Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 13Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 14Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 15Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 16
... complete line of enteric disease ... and monoclonal/polyclonal antibody-based ELISA tests ... pathogens in fecal specimens. Our ... difficile, Entamoeba histolytica, Giardia, Cryptosporidium ...
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: